Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

The benefits of pulmonary rehabilitation in patients with COVID-19

Zhen-feng He, Nan-shan Zhong, Wei-jie Guan
ERJ Open Research 2021 7: 00212-2021; DOI: 10.1183/23120541.00212-2021
Zhen-feng He
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan-shan Zhong
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
2Both authors contributed equally to the work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei-jie Guan
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
2Both authors contributed equally to the work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: battery203@163.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

This editorial reviews the evidence supporting benefits of pulmonary rehabilitation in #COVID19 patients, as well as some unanswered research questions https://bit.ly/39JY3SU

As of 10 March 2021, coronavirus disease 2019 (COVID-19) has resulted in more than 0.1 billion laboratory-confirmed cases and more than 2.5 million deaths globally [1]. Both the economic impact and disease burden of COVID-19 far exceeded those of severe acute respiratory syndrome and Middle East Respiratory Syndrome. The number of patients who have recovered from COVID-19 is increasing [2] despite an escalation of total number of cases worldwide.

The clinical manifestations of COVID-19 were heterogeneous, ranging from asymptomatic or mild diseases that did not require any specific medical treatment (accounting for ∼80% of patients) to the critical illness which rapidly progressed to death (accounting for ∼3% of patients) [3]. In many patients, COVID-19 was typically characterised by cough, dyspnoea and fever on hospital admission. Other symptoms such as fatigue, muscle weakness and dysgeusia have also been reported [4]. Unfortunately, a considerable proportion of patients had residual symptoms (including cough, fatigue, muscle weakness and mental symptoms) on discharge from hospital, and some of these symptoms persisted for at least a median of 6 months of follow-up [5]. Furthermore, the severity of COVID-19 correlated with the likelihood of having residual symptoms and abnormal lung function [5–7]. These findings were in line with the results from the long-term follow-up study among patients with severe acute respiratory syndrome which demonstrated that approximately 40% of these survivors still experienced chronic fatigue for a mean of 41.3 months [8].

Given the growing number of patients recovering from COVID-19 and the notable long-lasting adverse consequences, it is crucial for clinicians to explore novel approaches to help patients ameliorate the residual symptoms. Pulmonary rehabilitation (PR), which includes (but is not limited to) exercise training, education, and behavioural changes, might have a role in accelerating the improvement in the physical and psychological condition of patients with COVID-19 after discharge from hospital [9]. Indeed, several studies have also documented the therapeutic benefits of PR on improving the quality of life (QoL), respiratory function and psychological parameters of patients with COPD, asthma and lung cancer after thoracic surgery [10–12].

In the context of the global management of the aftermath of COVID-19, there remains a lack of evidence to verify the safety and efficacy of PR on patients discharged from hospital, although some expert consensus and guidelines have been published by the World Health Organization [13], Chinese Medical Association of Rehabilitation [14], and European Respiratory Society/American Thoracic Society [15]. These documents recommended early bedside in-hospital rehabilitation and regular daily activities after hospital discharge among patients with COVID-19 [15]. However, in light of the paucity of studies, no specific recommendations have been made regarding the optimal mode, intensity, duration and course of PR. It was believed that the implementation of a comprehensive PR programme would be superior to no PR programme in accelerating the recovery of COVID-19 [15].

In this issue of ERJ Open Research, Gloeckl et al. [16] evaluated the efficacy, feasibility and safety of an integrated PR programme in COVID-19 patients with different grading of disease severity. The study prospectively evaluated the improvement of exercise capacity, lung function, QoL and psychological impairment among 50 patients (24 with mild/moderate COVID-19 and 26 with severe/critical illness of COVID-19) after a 3-week supervised PR programme, which was similar to that intended for patients with lung fibrosis, in a rehabilitation centre. The medium duration between the first positive PCR assay and PR administration was 178 days and 61 days for the mild/moderate group and the severe/critical illness group, respectively. At the end of follow-up, there was a significant improvement in the 6-min walking distance (6 MWD), forced vital capacity, forced expiratory volume in 1 s, and short-form 36 questionnaire (SF-36) total score in both groups. Importantly, the severe/critical illness group benefited significantly from the improvement in the mental health component of SF-36. No adverse event was recorded during the PR. Moreover, a numerically but not significantly lower number of patients reported pre-existing symptoms such as dyspnoea, fatigue or cough after PR. Therefore, PR was deemed effective and safe to improve exercise performance, lung function and QoL in COVID-19 patients with different grading of disease severity.

The study by Gloeckl et al. [16] has added to the accumulating evidence regarding the role PR plays in accelerating the recovery of COVID-19. Several studies have reported certain benefits associated with the intervention of a short course of PR. For instance, both lower limb strength and cardiopulmonary endurance could be improved significantly after a supervised 2-week out-patient PR programme via the telehealth platform (65% of the 44 patients achieved the clinically meaningful difference) or home-based exercise programme (88% of the 25 patients achieved the clinically meaningful difference) [17]. A 28-day course of PR also markedly increased the 6 MWD in 21 patients with COVID-19 who were discharged from the intensive care unit [18]. In a prospective clinical trial that recruited 72 elderly patients with COVID-19 who were randomly assigned to receive either a 6-week PR programme or usual care alone, PR resulted in a marked improvement in the lung function, QoL and anxiety, but not depression [19]. Furthermore, a 20-day in-patient cardiopulmonary rehabilitation programme for 28 patients with COVID-19 in a general ward significantly improved the 6 MWD by a mean of 130 m as well as the health status [20]. Therefore, most studies found that PR consistently accelerated the recovery of physical function but the impact on mental health remains elusive. Indeed, the adverse impact of an epidemic outbreak such as COVID-19 and severe acute respiratory syndrome on mental health might persist longer than that on the physical health [5, 8]. Despite the lack of a control group, findings of the study by Gloeckl et al. [16] have also shed light on the positive role of PR in accelerating the recovery of mental health which has been an important neglected issue.

However, there remain some unanswered research questions. In light of the self-limited nature of COVID-19 among most of the patients, the improvement in 6 MWD might have been confounded by the rate of the natural recovery of COVID-19. Daher et al. [21] recruited a cohort of patients with severe COVID-19 who did not receive a PR programme, and reported a median of 380 m on the 6 MWD after ∼56 days of discharge from hospital which was significantly lower than the median of 468 m reported by Gloeckl et al. [16]. It was likely that the improvements in patients recovering from severe COVID-19 might be attributed to the addition of a PR programme. In addition, the PR programme varied considerably from one to other, which precluded any direct comparison of the efficacy across different study designs. However, the heterogeneity of COVID-19 also indicated the need to implement an individualised PR programme [22]. PR should ideally integrate respiratory muscle training, cough exercise, diaphragmatic training, stretching exercise and home exercise, with the assessment of respiratory function, exercise endurance, strength training, QoL and psychological health [19]. The typical duration of the PR programme should persist for at least 6–8 weeks [15]. Furthermore, the implementation of the PR programmes should be adapted to the local situations, taking into account the patient's preference and culture. Table 1 demonstrates the proposed interim instructions from the World Health Organization and European Respiratory Society/American Thoracic Society on PR practice in the hospital and post-hospital phase in COVID-19 patients based on empirical evidence.

View this table:
  • View inline
  • View popup
TABLE 1

Interim instructions on pulmonary rehabilitation practice in the acute, sub-acute and long-term phase in coronavirus disease 2019 patients

Despite the growing understanding on the role of PR, the generalisability of PR remains to be tested by well-designed randomised controlled trials in larger settings. We keenly await more solid evidence which will facilitate the implementation of PR in routine clinical practice, which aims to promote the physical and mental health in long-term follow-up for COVID-19 patients.

Acknowledgement

We thank Shan-shan Zha (Shenzhen People's Hospital) and Li-li Guan (Guangzhou Institute for Respiratory Health) for their valuable suggestions.

Footnotes

  • Author contributions: Zhen-feng He and Wei-jie Guan drafted the manuscript; Wei-jie Guan and Nan-shan Zhong critically revised the manuscript. All authors have approved the final submission.

  • Conflict of interest: Z-f. He has nothing to disclose.

  • Conflict of interest: N-s. Zhong has nothing to disclose.

  • Conflict of interest: W-j. Guan has nothing to disclose.

  • Support statement: This work was supported by the Guangzhou Institute for Respiratory Health Open Project (funded by China Evergrande Group) project numbers 2020GIRHHMS09 and 2020GIRHHMS19 (to W-j. Guan), the Zhongnanshan Medical Foundation of Guangdong Province (to W-j. Guan) and the Penghua Care Fund to the Medical Pioneers against Covid-19 of Shenzhen Social Commonwealth Foundation (to W-j. Guan). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received March 23, 2021.
  • Accepted March 24, 2021.
  • Copyright ©The authors 2021
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. World Health Organization
    . Coronavirus disease (COVID-19) pandemic. www.who.int/emergencies/diseases/novel-coronavirus-2019 Date last accessed: 10 March 2021.
  2. ↵
    1. Gautam AP,
    2. Arena R,
    3. Dixit S, et al.
    Pulmonary rehabilitation in COVID-19 pandemic era: the need for a revised approach. Respirology 2020; 25: 1320–1322. doi:10.1111/resp.13946
    OpenUrl
  3. ↵
    1. Guan WJ,
    2. Ni ZY,
    3. Hu Y, et al.
    Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720. doi:10.1056/NEJMoa2002032
    OpenUrlCrossRefPubMed
  4. ↵
    1. Giacomelli A,
    2. Pezzati L,
    3. Conti F, et al.
    Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis 2020; 71: 889–890. doi:10.1093/cid/ciaa330
    OpenUrlPubMed
  5. ↵
    1. Huang C,
    2. Huang L,
    3. Wang Y, et al.
    6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220–232. doi:10.1016/S0140-6736(20)32656-8
    OpenUrlCrossRefPubMed
    1. Xiong Q,
    2. Xu M,
    3. Li J, et al.
    Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect 2021; 27: 89–95. doi:10.1016/j.cmi.2020.09.023
    OpenUrlCrossRefPubMed
  6. ↵
    1. Carfi A,
    2. Bernabei R,
    3. Landi F
    . Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324: 603–605. doi:10.1001/jama.2020.12603
    OpenUrlCrossRefPubMed
  7. ↵
    1. Lam MH,
    2. Wing YK,
    3. Yu MW, et al.
    Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med 2009; 169: 2142–2147. doi:10.1001/archinternmed.2009.384
    OpenUrlCrossRefPubMed
  8. ↵
    1. Spruit MA,
    2. Singh SJ,
    3. Garvey C, et al.
    An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13–e64. doi:10.1164/rccm.201309-1634ST
    OpenUrlCrossRefPubMed
  9. ↵
    1. Prunera-Pardell MJ,
    2. Padin-Lopez S,
    3. Domenech-Del RA, et al.
    Effectiveness of a respiratory rehabilitation programme in patients with chronic obstructive pulmonary disease. Enferm Clin 2018; 28: 5–12. doi:10.1016/j.enfcli.2017.11.001
    OpenUrl
    1. Schneeberger T,
    2. Jarosch I,
    3. Moll J, et al.
    Increased asthma control after a 3-week inpatient pulmonary rehabilitation program. Respir Med 2020; 165: 105930. doi:10.1016/j.rmed.2020.105930
    OpenUrl
  10. ↵
    1. Wytrychowski K,
    2. Hans-Wytrychowska A,
    3. Piesiak P, et al.
    Pulmonary rehabilitation in interstitial lung diseases: a review of the literature. Adv Clin Exp Med 2020; 29: 257–264. doi:10.17219/acem/115238
    OpenUrl
  11. ↵
    1. Pan American Health Organization
    . Rehabilitation Considerations During the COVID-19 Outbreak. https://iris.paho.org/handle/10665.2/52035 Date last updated: 19 May 2020; date last accessed: 22 March 2021.
  12. ↵
    [Recommendations for respiratory rehabilitation of coronavirus disease 2019 in adult]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: 308–314.
    OpenUrl
  13. ↵
    1. Spruit MA,
    2. Holland AE,
    3. Singh SJ, et al.
    COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society and American Thoracic Society-coordinated international task force. Eur Respir J 2020; 56: 2002197. doi:10.1183/13993003.02197-2020
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Gloeckl R,
    2. Leitl D,
    3. Jarosch I, et al.
    Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res 2021; 7: 00108-2021.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Hameed F,
    2. Palatulan E,
    3. Jaywant A, et al.
    Outcomes of a COVID-19 recovery program for patients hospitalized withSARS-CoV-2 infection in New York City: a prospective cohort study. PM R 2021; in press. https://doi.org/10.1002/pmrj.12578
  16. ↵
    1. Al CY,
    2. Veale D,
    3. Schoeffler M, et al.
    Effectiveness of pulmonary rehabilitation in COVID-19 respiratory failure patients post-ICU. Respir Physiol Neurobiol 2021; 287: 103639. doi:10.1016/j.resp.2021.103639
    OpenUrl
  17. ↵
    1. Liu K,
    2. Zhang W,
    3. Yang Y, et al.
    Respiratory rehabilitation in elderly patients with COVID-19: a randomized controlled study. Complement Ther Clin Pract 2020; 39: 101166. doi:10.1016/j.ctcp.2020.101166
    OpenUrlPubMed
  18. ↵
    1. Hermann M,
    2. Pekacka-Egli A,
    3. Witassek F, et al.
    Feasibility and efficacy of cardiopulmonary rehabilitation after COVID-19. Am J Phys Med Rehab 2020; 99: 865–869. doi:10.1097/PHM.0000000000001549
    OpenUrlPubMed
  19. ↵
    1. Daher A,
    2. Balfanz P,
    3. Cornelissen C, et al.
    Follow up of patients with severe coronavirus disease 2019 (COVID-19): pulmonary and extrapulmonary disease sequelae. Respir Med 2020; 174: 106197. doi:10.1016/j.rmed.2020.106197
    OpenUrl
  20. ↵
    1. De Franca E,
    2. Junior UE,
    3. Schwingel PA, et al.
    Distinct phenotypes in COVID-19 may require distinct pulmonary rehabilitation strategies. Monaldi Arch Chest Dis 2020; 90. doi:10.4081/monaldi.2020.1523
PreviousNext
Back to top
Vol 7 Issue 2 Table of Contents
ERJ Open Research: 7 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The benefits of pulmonary rehabilitation in patients with COVID-19
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The benefits of pulmonary rehabilitation in patients with COVID-19
Zhen-feng He, Nan-shan Zhong, Wei-jie Guan
ERJ Open Research Apr 2021, 7 (2) 00212-2021; DOI: 10.1183/23120541.00212-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The benefits of pulmonary rehabilitation in patients with COVID-19
Zhen-feng He, Nan-shan Zhong, Wei-jie Guan
ERJ Open Research Apr 2021, 7 (2) 00212-2021; DOI: 10.1183/23120541.00212-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Asthma patients’ and physicians’ perspectives of disease burden
  • Important steps towards a big change for lung health
  • The BED-Pro Tool
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society